Clinical Trial

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2026-02-03; most recent amendment 2026-06-26.
Trial Details
NCT Number NCT07400029
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Autolus Limited
Conditions Acute Lymphoblastic Leukemia
Enrollment 40 participants
Start Date 2026-02-03
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-11